NCT06487000View on ClinicalTrials.gov

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

EC-18

oral administration, QD

DRUG

Placebo EC-18

oral administration, QD

Sponsors
All Listed Sponsors
lead

Enzychem Lifesciences Corporation

INDUSTRY